Q-omics provides the consensus-scored PSMD12 profile across patient tissues and cancer cell-line models. PSMD12 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PSMD12 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, PSMD12 protein abundance shows 22,373 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where PSMD12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PSMD12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PSMD12 survival associations across molecular data types. PSMD12 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PSMD12 RNA expression–survival associations across cancer types. High PSMD12 expression shows unfavorable associations in KIRP, HNSC, UVM, LIHC and LGG, but favorable associations in COAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PSMD12 RNA expression.
This table summarizes PSMD12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for PSMD12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PSMD12 shows lower tumor expression in KICH and higher tumor expression in HNSC, LUAD, BLCA, KIRC and LIHC. The HNSC box plot shows higher PSMD12 RNA expression in tumor versus normal tissue (log2 FC = +0.777, t-test p < 0.001).
This table shows molecular features associated with PSMD12 in patient tissues and cancer cell lines. In patient samples, PSMD12 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, PSMD12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
